Chouinard G, Goodman W, Greist J, Jenike M, Rasmussen S, White K, Hackett E, Gaffney M, Bick P A
McGill University, Montreal, Quebec, Canada.
Psychopharmacol Bull. 1990;26(3):279-84.
Eighty-seven patients with a DSM-III diagnosis of obsessive-compulsive disorder (OCD) without depression were entered into a double-blind, placebo-controlled study of the efficacy of sertraline, a new serotonin uptake inhibitor. After a 1-week washout period, patients were randomly assigned to receive either placebo or sertraline. After a 2-week titration period in which the once-daily sertraline dose was increased from 50 mg/day to a maximum of 200 mg/day, dosage was maintained until the end of the eighth week, then patients were titrated off medication over the next 2 weeks. Efficacy was measured by the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), NIMH General Obsessive-Compulsive Scale, Maudsley Obsessive Compulsive (MOC) Inventory, and Clinical Global Impressions (CGI) Severity and Improvement scales. Results on the MOC Inventory showed trends in favor of active drug that were not statistically significant compared with placebo. Results of the Y-BOCS total score, the NIMH score, and the global severity and improvement scores demonstrated a statistically significant superiority of sertraline compared with placebo.
87名被诊断患有强迫症（OCD）且无抑郁症状的患者参与了一项关于新型5-羟色胺摄取抑制剂舍曲林疗效的双盲、安慰剂对照研究。经过1周的洗脱期后，患者被随机分配接受安慰剂或舍曲林治疗。在为期2周的滴定期内，舍曲林的每日剂量从50毫克/天增加到最大200毫克/天，剂量维持至第八周结束，然后在接下来的2周内逐渐减少药物剂量。疗效通过耶鲁-布朗强迫症量表（Y-BOCS）、美国国立精神卫生研究所（NIMH）综合强迫症量表、莫兹利强迫症（MOC）问卷以及临床总体印象（CGI）严重程度和改善量表进行评估。MOC问卷的结果显示出有利于活性药物的趋势，但与安慰剂相比无统计学意义。Y-BOCS总分、NIMH评分以及总体严重程度和改善评分的结果表明，与安慰剂相比，舍曲林具有统计学上的显著优势。
